Liu, Joyce F <br/><br/>
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Sep 2013 
 - 2972-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2013.05.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Capsules<br/>Carcinoma, Ovarian Epithelial<br/>Diarrhea--chemically induced<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Fatigue--chemically induced<br/>Female<br/>Humans<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neoplasm Recurrence, Local<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Tablets<br/>Treatment Outcome